FLT-PET for Early Detection of Relapse in Patients With Irradiated Lung Cancer

This study investigates the feasibility of FLT-PET to improve the diagnosis of relapse in patients with irradiated lung cancer in comparison with FDG-PET/CT.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Lung Cancer, Nonsmall Cell Bronchial Neoplasms Carcinoma, Bronchogenic Carcinoma, Non-Small-Cell Lung Lung Diseases Lung Neoplasms Neoplasms Neoplasms by Site Respiratory Tract Diseases Respiratory Tract Neoplasms Small Cell Lung Cancer Small Cell Lung Carcinoma Thoracic Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Dept. Respiratory Medicine, Bispebjerg University Hospital, Copenhagen, Denmark

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

history with lung cancer, small cell or non-small cell
radiotherapy of lung cancer ended within the last 24 months
radiotherapy might be normofractionated or stereotactic
current suspicion of relapse
written and oral consent

Exclusion criteria

communication difficulties
pregnancy or lactation

Treatment and study plan

FLT-PET

Device

Primary outcomes

Number of patients with local and/or regional relapse

Time frame: 6 months

Sponsors and collaborators

Lead sponsor

Rigshospitalet, Denmark

Other

Registry information

Important dates

Study start: 2014
Primary completion: 2019
Study completion: 2020
First posted: Dec 19, 2016
Registry last updated: May 9, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed